Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-24. ← Back to Evidence Library

SNAP-8: what the evidence says

Acetyl octapeptide-3 · Acetyl glutamyl heptapeptide-1 · Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2

Status: Approved for Adam Greene by Dr. Nova Reyes, 2026-10-24 · Last checked: Oct 24, 2026

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

---

1. What it is and what people claim it does

SNAP-8 (acetyl octapeptide-3, also listed in older cosmetic registries as acetyl glutamyl heptapeptide-1, sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) is a synthetic octapeptide (8-amino-acid chain) developed by the Spanish cosmetic raw-material company Lipotec S.A. (now Lubrizol Life Science). ^{R2, R6} It is an elongated version of Lipotec's earlier cosmetic hexapeptide Argireline (acetyl hexapeptide-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, first described by Blanes-Mira et al. in 2002 ^R1), with two extra amino acids (alanine and aspartate) added to the C-terminal end.

The "topical Botox" theory—and why skin physics get in the way

Whenever a facial nerve tells a muscle to squint or frown, the nerve ending must release the chemical messenger acetylcholine (a neurotransmitter that triggers muscle contraction). To fuse acetylcholine-filled vesicles (tiny storage sacs) with the nerve membrane, three proteins must zip together into a tight bundle called the SNARE complex (soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex): VAMP, Syntaxin, and SNAP-25. ^{R1, R6}

• Prescription botulinum neurotoxin (Botox, Dysport, Xeomin) is a large bacterial enzyme injected directly into facial muscles, where it enters nerve endings and chemically cuts (cleaves) the SNAP-25 protein, paralyzing the muscle for months.
• SNAP-8 does not cut anything. Instead, its 8-amino-acid sequence copies a tiny fragment of the N-terminal end of SNAP-25. In cell-free test tubes and cultured neurons, fragments like Argireline and SNAP-8 compete with native SNAP-25 for a spot in the SNARE bundle, slightly destabilizing vesicle docking and reducing catecholamine or neurotransmitter release. ^{R1, R6, R7}

However, for a topical cream to relax a facial muscle in a living person, the molecule has to cross the stratum corneum (the tough, waterproof outer barrier of dead skin cells), diffuse through the entire epidermis and dermis (the upper and deeper layers of skin), and enter motor nerve terminals inside the underlying facial muscle. Because SNAP-8 is a charged, water-loving (hydrophilic) 8-amino-acid peptide with a molecular weight of 1,075.16 Daltons—well above the classic 500-Dalton rule (the size threshold above which water-soluble molecules poorly penetrate intact skin)—very little intact peptide crosses normal skin on its own. ^{R6, R7}

---

2. What the human evidence actually shows

The Open Peptide Project's reading: Very limited for topical cosmetic wrinkle reduction (multi-ingredient products only; zero peer-reviewed single-ingredient controlled trials), and No human data (nothing at all) for subcutaneous injection.

Indication	Route studied	Evidence rating	Summary of human studies
Facial fine lines and periorbital ("crow's-feet") wrinkles	Topical multi-ingredient serums, creams, or dissolving hyaluronic-acid microneedle patches	Very limited	Four peer-reviewed human studies (24 to 50 adults enrolled) report modest improvements in skin roughness or wrinkle depth using multi-ingredient cosmetic products that combine acetyl octapeptide-3 with hyaluronic acid microneedles, vitamin C derivatives, cyclic lysophosphatidic acid, seaweed extracts, or 3–5 other peptides. No peer-reviewed human trial has tested single-ingredient SNAP-8 against its own plain base cream. R2–R5
Injectable facial wrinkle paralysis ("DIY injectable SNAP-8")	Subcutaneous or intramuscular injection	No human data	Nothing at all: Zero human or animal studies have ever injected SNAP-8 under the skin or into muscle.

What the published human skincare trials actually tested

1. Dissolving hyaluronic-acid microneedle patches (Avcil et al., 2020; Shin et al., 2024):
2. Because octapeptides struggle to cross the outer skin barrier, cosmetic formulators began embedding acetyl octapeptide-3 into dissolving hyaluronic-acid microneedle patches (tiny water-soluble cones pressed onto crow's-feet that dissolve in the upper epidermis).
3. In a 2020 single-arm study of 29 adults (Avcil et al.), a hyaluronic-acid microneedle patch loaded with acetyl octapeptide-3 plus palmitoyl tripeptide-5, arginine/lysine polypeptide, adenosine, and seaweed extract improved hydration, skin density, and fine-line roughness. Because there was no placebo patch and five active ingredients were mixed together, the study could not measure SNAP-8's individual effect. ^R2
4. In a 2024 split-face study of 24 healthy Korean adults (Shin et al.), participants applied a dissolving hyaluronic-acid microneedle patch containing acetyl octapeptide-3, L-ascorbic acid 2-glucoside (a vitamin C derivative), and sodium cyclic lysophosphatidic acid (cPA) around one eye and a plain hyaluronic-acid placebo microneedle patch around the other eye during the test period (schedule in Study details). Eye wrinkle parameters, transepidermal water loss (TEWL, water evaporation from the skin), elasticity, and lifting improved compared with the plain hyaluronic-acid patch without adverse reactions—but because three active ingredients were loaded together, the trial could not separate SNAP-8's effect from the vitamin C derivative and cPA. ^R5
5. Multi-peptide topical serums (Moy et al., 2023; Draelos & Diaz, 2023):
6. Two industry-sponsored single-arm US trials tested commercial multi-peptide serums containing acetyl octapeptide-3 alongside several other peptides, antioxidants, botanical extracts, and humectants (moisture-binding ingredients) in 31 subjects (Moy et al., 2023) ^R3 and 50 women (47 completed) (Draelos & Diaz, 2023) ^R4. Both reported improvements in investigator-graded smoothness, hydration, firmness, and fine lines (doses and durations in Study details), and neither trial had a vehicle-only control group to isolate SNAP-8 from the hydrating base and co-formulated actives.
7. Unpublished manufacturer datasheet claim <span class="tag unverified">UNVERIFIED</span>:
8. Cosmetic review articles and commercial brochures frequently repeat a claim from a Lipotec/Lubrizol technical datasheet that a topical cream containing acetyl octapeptide-3 reduced wrinkle depth by "up to 63%" (or averaged ~35%) in a small internal split-face volunteer test. ^{R3, R6} Because that manufacturer report has never been published as a peer-reviewed paper with full methods, raw data, or statistical tables, we mark it [UNVERIFIED: unpublished manufacturer datasheet claim].

---

3. Known risks, side effects, and long-term unknowns

• Topical use (creams, serums, patches): Across published cosmetic studies and cosmetic safety reviews of acetylated SNARE-mimetic peptides, topical application to intact skin causes very few side effects—mainly occasional mild contact redness, itching, or stinging from preservatives or penetration enhancers in the vehicle. ^{R2–R5, R8}
• Subcutaneous injection of gray-market vials (major warning): Some gray-market "research peptide" websites sell SNAP-8 as a lyophilized powder in crimped glass injection vials alongside BPC-157 and Melanotan-II, leading buyers on social media to reconstitute (mix) it with bacteriostatic water (sterile water with a preservative) and inject it subcutaneously into their forehead or around their eyes.
• Zero human or animal injection safety data: SNAP-8 was engineered strictly as a topical cosmetic raw material (Acetyl Octapeptide-3). It has never undergone preclinical toxicology, neurotoxicity, or clinical safety testing as an injectable drug.
• Risk of unintended local nerve/muscle effects, granulomas, and infection: Injecting a synthetic SNARE-competing peptide and cosmetic-grade synthesis impurities directly into the thin tissues around the eye or forehead carries unknown risks of uneven muscle weakness, eyelid droop (ptosis), foreign-body granulomas (hard inflammatory lumps under the skin), cellulitis (deep bacterial skin infection), and systemic immune sensitization.

---

4. Regulatory and compounding status

Jurisdiction / Body	Current Status	Details
United States (FDA — Drugs@FDA & Cosmetics)	Cosmetic ingredient only (Not an FDA-approved drug)	Listed in the International Nomenclature of Cosmetic Ingredients (INCI) as Acetyl Octapeptide-3 (and Acetyl Glutamyl Heptapeptide-1) for topical skin-conditioning products. Under the US Federal Food, Drug, and Cosmetic Act, any product claiming to paralyze muscles or alter skin structure like an injectable neurotoxin is an unapproved new drug, not a cosmetic. Checked via openFDA Oct 24, 2026: zero approved drug products. R9
United States (FDA — 503A / 503B Compounding)	Not on 503A or 503B compounding lists	Acetyl octapeptide-3 has no USP/NF drug monograph, is not a component of any FDA-approved drug, and does not appear on FDA's 503A Positive List or 503B Bulks List for compounding injectable medications.
European Union (CosIng / EMA)	Cosmetic ingredient (CosIng); not an authorised medicine	Listed in the European Commission's CosIng database as a topical humectant/skin-conditioning ingredient; not approved by the EMA as a medicinal product. R6
World Anti-Doping Agency (WADA 2026)	Not prohibited as a topical cosmetic	Acetyl octapeptide-3 is not listed on the 2026 WADA Prohibited List. R10

---

5. Quality, contamination, and gray-market risks

1. Cosmetic raw material repackaged in sterile-looking injection vials: Authentic cosmetic-grade SNAP-8 is sold to skincare manufacturers as an aqueous solution (diluted in water with phenoxyethanol or caprylyl glycol preservatives) or bulk non-sterile powder meant for topical creams. Gray-market peptide vendors buy bulk non-sterile cosmetic powder from chemical suppliers, freeze-dry it into glass vials with flip-off caps, and sell it next to injectable peptides—creating the false impression that it is sterile, pyrogen-free (free of bacterial fever toxins), and meant for injection.
2. Peptide content and sequence swapping (Argireline vs SNAP-8): Because Argireline (6 amino acids, MW 889 Da) is cheaper to synthesize than SNAP-8 (8 amino acids, MW 1,075 Da), unverified vials or raw powders can contain Argireline, truncated 6- or 7-mer deletion sequences, or mostly mannitol (sugar-alcohol) filler unless verified by liquid chromatography–mass spectrometry (LC-MS).
3. Blind retail testing: We test retail vials blind under the Open Peptide Standard. See results at /tests/. A passing test covers one batch, tested on one date. It does not mean the compound itself is safe.

---

6. Who should be especially cautious

• Anyone considering injecting a gray-market SNAP-8 vial: Do not inject SNAP-8. It is a topical cosmetic ingredient with zero human or animal injection safety data.
• People with neuromuscular disorders (such as myasthenia gravis or Lambert-Eaton syndrome): Avoid applying SNARE-targeted peptides to broken skin, open wounds, or mucous membranes, or combining them with aggressive deep microneedling where systemic absorption has not been studied.
• People with eczema, rosacea, or compromised skin barriers around the eyes: Penetration enhancers and preservatives in topical peptide serums or microneedle patches can trigger contact dermatitis.
• Pregnant or breastfeeding women: While topical intact-skin absorption of a 1,075-Dalton octapeptide is expected to be very low, systemic reproductive safety has never been studied.

---

7. Open questions and research gaps

1. Does SNAP-8 outperform its plain moisturizing base cream in an independent, double-blind, vehicle-controlled human trial? Until a trial tests base cream + SNAP-8 head-to-head against the exact same base cream alone (and against Argireline), nobody knows whether the extra two amino acids improve real-world wrinkle reduction in human skin or simply hydrate the outer layer.
2. How much intact SNAP-8 actually reaches human facial motor nerve terminals in vivo? In vitro (lab-dish) Franz-diffusion skin-permeation studies show that standard aqueous solutions barely cross intact stratum corneum (<0.5%), raising the question of whether clinical smoothing in topical trials comes from epidermal hydration rather than neuromuscular SNARE inhibition. ^{R6, R7}

Study details

These are topical cosmetic regimens researchers tested, not medical recommendations.

Study (Year)	Design & Population	Route, Dose & Schedule	Primary / Key Outcomes	Adverse Events & Dropouts	Funding & Disclosures
Avcil et al. (2020) R2	Open-label, single-arm monocentric clinical and dermatological evaluation; 29 adults with facial fine lines and wrinkles	Topical dissolving microneedle patch: Hyaluronic-acid microneedle patches containing acetyl octapeptide-3 plus palmitoyl tripeptide-5, arginine/lysine polypeptide, adenosine, and seaweed extract, applied to crow's-feet and forehead for 12 weeks	Improved stratum corneum hydration (+15%), dermal thickness/density by ultrasound, and reduced mean wrinkle roughness/surface area by profilometry (~10%–25% across facial sites); no placebo or vehicle patch arm to isolate acetyl octapeptide-3.	Well tolerated; mild transient patch-site redness; 0 serious adverse events.	Sponsored by Patchlica / microneedle patch developer (South Korea / Turkey).
Moy et al. (2023) R3	Open-label, single-arm clinical trial (plus ex vivo skin model); 31 adults with mild-to-moderate facial expression lines	Topical multi-ingredient serum: Commercial peptide-pro complex serum containing acetyl octapeptide-3, dipeptide diaminobutyroyl benzylamide diacetate (Syn-Ake), acetyl hexapeptide-8, pentapeptide-18, proteins, amino acids, and marine extracts applied twice daily for 12 weeks	Statistically significant improvements in investigator-graded expression lines and digital wrinkle metrics at week 12 vs baseline; single-arm clinical design with multiple neuropeptides + humectants, no vehicle control.	No serious treatment-related adverse events reported.	Funded by PCA Skin / Colgate-Palmolive Company.
Draelos & Diaz (2023) R4	Open-label, single-center monadic clinical study; 50 female subjects enrolled (47 completed), ages 35–65, Fitzpatrick skin types I–VI with mild-to-moderate facial photoaging	Topical multi-peptide serum: Multimechanistic antiaging serum containing humectants, antioxidants, and peptides (including acetyl octapeptide-3), applied twice daily for 24 weeks (evaluated beginning at week 1 through week 24)	At 24 weeks: +19% skin firmness and +35% skin hydration by corneometry/bio-instrumentation; investigator-assessed 40% improvement in fine lines, 23% improvement in wrinkles, 58% in plumping, and 45% in overall appearance (starting at week 1); no placebo or vehicle control arm.	3 dropouts (47/50 completed); excellent tolerability, no serious adverse events.	Industry-sponsored cosmetic contract research study (Dermatology Consulting Services, High Point, NC).
Shin et al. (2024) R5	Split-face comparative clinical trial; 24 healthy Korean adults enrolled	Topical dissolving microneedle patch (DA-MNP): Droplet-extension hyaluronic-acid microneedle patch loaded with acetyl octapeptide-3, L-ascorbic acid 2-glucoside, and sodium cyclic lysophosphatidic acid (cPA) applied overnight to one eye vs plain hyaluronic-acid placebo microneedle patch on the other eye for 28 days	DA-MNP improved eye wrinkles, reduced transepidermal water loss (TEWL), and enhanced skin elasticity and eye lifting compared with the plain hyaluronic-acid placebo patch; could not isolate acetyl octapeptide-3 from the co-loaded ascorbic acid 2-glucoside and cPA.	No adverse skin effects reported over 28 days.	Supported by Korean cosmetic R&D / university collaboration (Seoul, South Korea).

---

8. References

1. ^R1 Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303–310. PMID 18498523
2. ^R2 Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020;19(2):328–337. PMID 31134751
3. ^R3 Moy M, Diaz I, Lesniak E, Giancola G. Peptide-pro complex serum: Investigating effects on aged skin. J Cosmet Dermatol. 2023;22(1):267–274. PMID 35426243
4. ^R4 Draelos ZD, Diaz I. The Benefits of a Multimechanistic Antiaging Skin Technology. Dermatol Ther (Heidelb). 2023;13(12):3111–3119. PMID 37861918
5. ^R5 Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024;36(4):215–224. PMID 39082657
6. ^R6 Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. PMID 33195061
7. ^R7 Pintea A, Manea A, Pintea C, Vlad RA, Bîrsan M, Antonoaea P, Rédai EM, Ciurba A. Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. Biomolecules. 2025;15(1):88. PMID 39858482; and Badilli U, Inal O. Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers. Polymers (Basel). 2025;17(6):798. PMID 40292641
8. ^R8 Johnson W Jr, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, et al. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025;44(2_suppl):54S–63S. PMID 40673537
9. ^R9 U.S. Food and Drug Administration. Cosmetics & U.S. Law: Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) and Drugs@FDA search (checked Oct 24, 2026: no FDA-approved drug products containing acetyl octapeptide-3 / SNAP-8). FDA Cosmetics vs Drugs Guidance
10. ^R10 World Anti-Doping Agency (WADA). The World Anti-Doping Code International Standard: Prohibited List (January 2026). WADA Prohibited List

---

Disclaimer

This page is for education and harm reduction. It is not medical advice and not a recommendation to use this compound. Please talk to a clinician you trust before making medical decisions, and report adverse events to FDA MedWatch (https://www.fda.gov/safety/medwatch).